- Home
- MNMD vs TEN Comparison
MNMD vs TEN Comparison
Compare MNMD & TEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- TEN
- Stock Information
- Founded
- MNMD 2019
- TEN 1993
- Country
- MNMD United States
- TEN Greece
- Employees
- MNMD N/A
- TEN N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- TEN
- Sector
- MNMD Health Care
- TEN
- Exchange
- MNMD Nasdaq
- TEN NYSE
- Market Cap
- MNMD 509.2M
- TEN 595.6M
- IPO Year
- MNMD N/A
- TEN N/A
- Fundamental
- Price
- MNMD $7.17
- TEN $19.93
- Analyst Decision
- MNMD Strong Buy
- TEN Buy
- Analyst Count
- MNMD 7
- TEN 2
- Target Price
- MNMD $26.29
- TEN $30.50
- AVG Volume (30 Days)
- MNMD 1.2M
- TEN 477.5K
- Earning Date
- MNMD 08-12-2025
- TEN 06-17-2025
- Dividend Yield
- MNMD N/A
- TEN 7.31%
- EPS Growth
- MNMD N/A
- TEN N/A
- EPS
- MNMD N/A
- TEN 4.46
- Revenue
- MNMD N/A
- TEN $799,523,000.00
- Revenue This Year
- MNMD N/A
- TEN N/A
- Revenue Next Year
- MNMD N/A
- TEN $9.46
- P/E Ratio
- MNMD N/A
- TEN $4.60
- Revenue Growth
- MNMD N/A
- TEN N/A
- 52 Week Low
- MNMD $4.70
- TEN $13.40
- 52 Week High
- MNMD $10.44
- TEN $29.82
- Technical
- Relative Strength Index (RSI)
- MNMD 52.28
- TEN 60.49
- Support Level
- MNMD $6.40
- TEN $18.93
- Resistance Level
- MNMD $7.20
- TEN $20.50
- Average True Range (ATR)
- MNMD 0.43
- TEN 0.86
- MACD
- MNMD -0.03
- TEN -0.03
- Stochastic Oscillator
- MNMD 76.03
- TEN 67.38
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.